Organization Profile

You just read:

Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

News provided by

Oncothyreon Inc.

Apr 07, 2014, 06:00 ET